COVID-19: Get Vaccinated. Get Tested. Visitor Guidelines. Please use ER for Emergency Issues only.


  • A051301 A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in patients with relapsed or refractory Diffuse Large B-cell Lymphoma of the Activated B-cell Subtype
  • A051701 Randomized Phase II/III Study of Venetoclax (ABT 199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double-Expressing Lymphomas
  • EA4151 Rituximab with or Without Stem Cell Transplant in Treating Patients with Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
  • E4412  A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
  • S1826    A Phase III, randomized study of Nivolumab plus AVD or Brentuximab Vedotin plus AVD in patients with newly diagnosed advanced stage classical Hodgkin Lymphoma
  • EA4181 A Randomized 3-Arm Phase II study comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib, and 3.) Bendamustine, Rituximab and Acalabrutinib in patients < 70 years old with untreated Mantle Cell Lymphoma
  • U16092  Low-Dose Ibuprofen in Improving Cognitive Impairment in Patients With Non-metastatic Cancer